Roche’s Genentech unit just released a mid-stage study of a drug that seeks to slow the progression of Alzheimer’s by blocking the accumulation of a protein called amyloid beta. Like every other medicine that has attempted this approach – which remains the main one being pursued by drug companies to battle Alzheimer’s – the drug failed to yield a statistically significant benefit.
Hey, check out all the research scientist jobs. Post your resume today!
